The American Thoracic Society International Conference in Orlando, Florida, showcased a transformative era for Chronic Obstructive Pulmonary Disease (COPD) treatment, emphasizing a shift toward precision medicine and technology-driven care.
A pooled analysis of the Phase III METREX, METREO, and MATINEE trials confirmed that mepolizumab, added to inhaled triple therapy, reduced severe exacerbations requiring hospitalization by 23% in patients with an eosinophil count above 150 cells/μL. A complementary analysis supported the use of blood eosinophils as a key biomarker for targeting anti-IL-5 therapy.
Beyond biologics, the dual PDE3/PDE4 inhibitor ensifentrine emerged as a practical non-biologic add-on. Real-world data from the RELIEF study showed patients on stable triple therapy experienced improved CAT scores. A separate analysis of 2,372 patients confirmed an 11% reduction in severe exacerbations after initiating the therapy.
Artificial intelligence is also redefining diagnostic precision. Analyses from the SOURCE and COPDGene cohorts utilized AI-based algorithms for automated detection of mucus plugs on CT scans. The AI-assisted phenotyping linked greater mucus plug burden to higher mortality risk and worse quality of life, positioning the feature as a quantifiable biomarker for risk stratification.
Digital health tools received significant attention for expanding access. The Cough Search software demonstrated 92% sensitivity in diagnosing COPD via AI-based cough analysis, while machine-learning-driven smartphone spirometry showed strong agreement with conventional tests, capturing critical diurnal variations.
Despite clinical advances, real-world delivery remains a critical hurdle. The US DUALITY disparities study of over 338,000 patients found only 6.9% initiated triple therapy within a year of a severe exacerbation. Furthermore, another study reported 34.5% of COPD patients face food or financial insecurity, underscoring the need to address social determinants in routine care.